Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas

Cancer Cancer
Genomics Genomics
Immunology Immunology
Medicine Medicine
Alex K. Shalek Alex K. Shalek
Sam Kazer Sam Kazer

Amoozgar et al.▾ Amoozgar, Z., Kloepper, J., Ren, J., Tay, R.E., Kazer, S.W., Kiner, E., Krishnan, S., Posada, J.M., Ghosh, M., Mamessier, E., Wong, C., Ferraro, G.B., Batista, A., Wang, N., Badeaux, M., Roberge, S., Xu, L., Huang, P., Shalek, A.K., Fukumura, D., Kim, H.-J., Jain, R.K.

Nature Communications , Volume 12

May, 2021


Immune checkpoint blockers (ICBs) have failed in all phase III glioblastoma (GBM) trials. Here, we show that regulatory T (Treg) cells play a key role in GBM resistance to ICBs in experimental gliomas. Targeting glucocorticoid-induced TNFR-related receptor (GITR) in Treg cells using an agonistic antibody (αGITR) promotes CD4 Treg cell differentiation into CD4 effector T cells, alleviates Treg cell-mediated suppression of anti-tumor immune response, and induces potent anti-tumor effector cells in GBM. The reprogrammed GBM-infiltrating Treg cells express genes associated with a Th1 response signature, produce IFNγ, and acquire cytotoxic activity against GBM tumor cells while losing their suppressive function. αGITR and αPD1 antibodies increase survival benefit in three experimental GBM models, with a fraction of cohorts exhibiting complete tumor eradication and immune memory upon tumor re-challenge. Moreover, αGITR and αPD1 synergize with the standard of care treatment for newly-diagnosed GBM, enhancing the cure rates in these GBM models.